New drug shows promise for Sjögren's syndrome in early trial

NCT ID NCT04078386

Completed Disease control Sponsor: RemeGen Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a biologic drug called RC18 in 42 people with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. Participants received weekly injections of either RC18 (at 160 mg or 240 mg) or a placebo for 24 weeks. The goal was to see if RC18 could safely reduce disease activity, measured by a standard score (ESSDAI). The study is complete, and results may show whether RC18 can help control this chronic condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RC18 (a biologic drug that blocks a protein involved in immune system activity)
What this could lead to: If it works, this could lead to a new treatment option to control disease activity in people with primary Sjögren's syndrome.
What could go wrong: This is an early phase 2 trial with only 42 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SJÖGREN'S SYNDROME

Contacts and locations

Locations

Beijing Hospital

Beijing, China
Huzhou Third Municipal Hospital

Huzhou, Zhejiang, China
Peking Union Medical College Hospital

Beijing, China
Pingxiang People's Hospital

Pingxiang, Jiangxi, China
Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China
The First Affiliated Hospital of Bengbu Medical University

Bengbu, Anhui, China
The First Affiliated Hospital of USTC，Anhui Provincial Hospital

Hefei, Anhui, China
The First Affiliated Hospital of Xiamen University

Xiamen, China
The First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China
The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, China
The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, China
Tianjin Medical University General Hospital

Tianjin, China
West China School of Medicine，West China Hospital of Sichuan University

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.